NCT03259503View on ClinicalTrials.gov

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Hodgkin LymphomaRefractory T-Cell Non-Hodgkin Lymphoma
Interventions
DRUG

Busulfan

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Melphalan

Given IV

DRUG

Olaparib

Given PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo peripheral blood stem cell transplant

OTHER

Pharmacokinetic Study

Correlative studies

BIOLOGICAL

Rituximab

Given IV

DRUG

Vorinostat

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER